ALD-R491
A vimentin inhibitor.
General information
ALD-R491 is a small molecule targeting vimentin. It is not cytotoxic and does not change vimentin levels. ALD-R491 inhibits endocytosis, endosomal trafficking, and release of exosomes (Li et al., 2021).
Synonyms
R491; (E)-1-(4-fluorophenyl)-3-(4-((4-morpholin-4-yl-6-styryl-1,3,5-triazin-2-yl)amino)phenyl)urea
FC1=CC=C(C=C1)NC(=O)NC1=CC=C(C=C1)NC1=NC(=NC(=N1)N1CCOCC1)\C=C\C1=CC=CC=C1
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases
Small molecule Animal model In vitro Extracellular vesicles |
hACE2-HEK293 cells; U87 cells; Raw264.7 cells; Treg cells; mouse peritoneal macrophages; SD rats; BALB/c mice; SARS-CoV-2 Spike pseudovirus; mouse-adapted SARS-CoV-2 | 7.87 | ALD-R491 blocked endocytosis, endosomal trafficking, and release of exosomes. It also inhibited SARS-CoV-2 pseudovirus infection with an IC50 of 13.5 nM (at MOI of 0.5) and high selectivity. Experimental data suggest that it boosts the pathogen-killing capacity of macrophages and activates regulatory T cells. The compound displayed efficacy against SARS-CoV-2 infection in aged mice and in a rat model of lung injury. |
Oct/12/2021 |
